2016年 2月 9日
The final results of an independent evaluation of the US Food and Drug Administration’s medical device review program have been published, giving the agency high marks for efforts to improve review processes.
Mandated by the Medical Device User Fee Amendments of 2012 (MDUFA III), the evaluation of the FDA included two phases of assessment carried out by the Booz Allen Hamilton consultancy. The first phase involved establishing 11 best practices and process improvements the FDA’s Center for Devices and Radiological Health (CDRH) could implement for more consistent and efficient premarket reviews.
In the second phase of the assessment, Booz Allen Hamilton evaluated CRDH’s efforts to implement recommended process improvements, and determined that the FDA unit is on track to adequately meet those recommendations. The recommendations covered several CDRH areas, but prioritized certain projects:
“The initial results for a subset of the projects provide a positive indication that CDRH has promoted and begun using the products of their implementation projects,” states the report, but Booz Allen Hamilton acknowledges that more time will be needed to fully assess how successfully CDRH implements and maintains some of these projects—and how those projects impact US premarket review processes.